An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer
Oncologist - United States
doi 10.1634/theoncologist.2012-0129
Full Text
Open PDFAbstract
Available in full text
Date
May 22, 2013
Authors
Publisher
Alphamed Press